drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00095 | DB06372 | 66 | 259 | [
"DDInter623",
"DDInter1594"
] | Efalizumab | Rilonacept | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
66,
24,
259
]
],
[
[
66,
23,
1114
],
[
1114,
62,
259
]
],
[
[
66,
23,
1461
],
[
1461,
23,
259
]
],
[
[
66,
24,
0
],
[
0,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E... |
DB00196 | DB01268 | 600 | 1,151 | [
"DDInter743",
"DDInter1731"
] | Fluconazole | Sunitinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
600,
24,
1151
]
],
[
[
600,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
600,
21,
29269
],
[
29269,
60,
1151
]
],
[
[
600,
23,
1247
],
[
1247,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Fluconazole (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Su... |
DB00445 | DB00631 | 322 | 372 | [
"DDInter655",
"DDInter405"
] | Epirubicin | Clofarabine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
322,
24,
372
]
],
[
[
322,
64,
1064
],
[
1064,
25,
372
]
],
[
[
322,
24,
1585
],
[
1585,
40,
372
]
],
[
[
322,
5,
11555
],
[
11555,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribin... | Epirubicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine (Compound) resembles Clofa... |
DB00475 | DB01181 | 1,119 | 1,532 | [
"DDInter355",
"DDInter906"
] | Chlordiazepoxide | Ifosfamide | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1119,
24,
1532
]
],
[
[
1119,
6,
8374
],
[
8374,
45,
1532
]
],
[
[
1119,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
1119,
24,
401
],
[
401,... | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} ... | Chlordiazepoxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound)
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Chlo... |
DB00851 | DB01033 | 611 | 328 | [
"DDInter463",
"DDInter1156"
] | Dacarbazine | Mercaptopurine | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
611,
24,
328
]
],
[
[
611,
5,
11555
],
[
11555,
44,
328
]
],
[
[
611,
62,
1299
],
[
1299,
23,
328
]
],
[
[
611,
63,
663
],
[
663,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Dacarbazine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (... | Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Mercaptopurine (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when... |
DB00065 | DB00333 | 581 | 576 | [
"DDInter923",
"DDInter1166"
] | Infliximab | Methadone | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
581,
24,
576
]
],
[
[
581,
24,
494
],
[
494,
40,
576
]
],
[
[
581,
63,
491
],
[
491,
23,
576
]
],
[
[
581,
24,
112
],
[
112,
62,... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Methadone (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a minor ... |
DB09065 | DB11901 | 760 | 913 | [
"DDInter424",
"DDInter107"
] | Cobicistat | Apalutamide | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
760,
25,
913
]
],
[
[
760,
64,
312
],
[
312,
23,
913
]
],
[
[
760,
63,
608
],
[
608,
23,
913
]
],
[
[
760,
62,
271
],
[
271,
23,... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} ... | Cobicistat may lead to a major life threatening interaction when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a m... |
DB01050 | DB09061 | 848 | 1,627 | [
"DDInter900",
"DDInter284"
] | Ibuprofen | Cannabidiol | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
848,
24,
1627
]
],
[
[
848,
63,
723
],
[
723,
23,
1627
]
],
[
[
848,
24,
384
],
[
384,
23,
1627
]
],
[
[
848,
24,
1613
],
[
1613,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisi... |
DB00196 | DB01227 | 600 | 1,301 | [
"DDInter743",
"DDInter1043"
] | Fluconazole | Levacetylmethadol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
600,
25,
1301
]
],
[
[
600,
25,
494
],
[
494,
1,
1301
]
],
[
[
600,
23,
307
],
[
307,
1,
1301
]
],
[
[
600,
24,
675
],
[
675,
1,... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",... | Fluconazole may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Levacetylmethadol (Compound)... |
DB01064 | DB08865 | 1,148 | 1,593 | [
"DDInter987",
"DDInter448"
] | Isoprenaline | Crizotinib | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1148,
25,
1593
]
],
[
[
1148,
7,
4759
],
[
4759,
46,
1593
]
],
[
[
1148,
18,
6509
],
[
6509,
57,
1593
]
],
[
[
1148,
21,
28921
],
[
28... | [
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Isoprenaline",
"{u} (Compound) upregulates {v} (Gene)",
"SERPINA3"
],
[
"SERPINA3",
"{u} (Gene) is upregulated by {v} (Compou... | Isoprenaline (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Crizotinib (Compound)
Isoprenaline (Compound) downregulates EIF5 (Gene) and EIF5 (Gene) is downregulated by Crizotinib (Compound)
Isoprenaline (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Criz... |
DB00146 | DB00880 | 160 | 359 | [
"DDInter265",
"DDInter360"
] | Calcifediol | Chlorothiazide | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
160,
24,
359
]
],
[
[
160,
24,
1577
],
[
1577,
1,
359
]
],
[
[
160,
25,
1196
],
[
1196,
63,
359
]
],
[
[
160,
36,
386
],
[
386,
... | [
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
... | Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Calcifediol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate inter... |
DB00046 | DB01124 | 1,179 | 1,411 | [
"DDInter940",
"DDInter1828"
] | Insulin lispro | Tolbutamide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1179,
24,
1411
]
],
[
[
1179,
24,
959
],
[
959,
40,
1411
]
],
[
[
1179,
23,
721
],
[
721,
62,
1411
]
],
[
[
1179,
23,
333
],
[
333,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and Methylcellulose may cause a minor interactio... |
DB00393 | DB08816 | 854 | 578 | [
"DDInter1295",
"DDInter1802"
] | Nimodipine | Ticagrelor | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Minor | 0 | [
[
[
854,
23,
578
]
],
[
[
854,
6,
8374
],
[
8374,
45,
578
]
],
[
[
854,
21,
28762
],
[
28762,
60,
578
]
],
[
[
854,
1,
336
],
[
336,
... | [
[
[
"Nimodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Nimodipine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Nimodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limi... |
DB01018 | DB01222 | 1,364 | 617 | [
"DDInter847",
"DDInter246"
] | Guanfacine | Budesonide | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1364,
24,
617
]
],
[
[
1364,
63,
251
],
[
251,
1,
617
]
],
[
[
1364,
25,
1220
],
[
1220,
1,
617
]
],
[
[
1364,
6,
8374
],
[
8374,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Guanfacine may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Compound)
Gua... |
DB01030 | DB11817 | 869 | 1,259 | [
"DDInter1835",
"DDInter165"
] | Topotecan | Baricitinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
869,
25,
1259
]
],
[
[
869,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
869,
24,
949
],
[
949,
24,
1259
]
],
[
[
869,
63,
563
],
[
563,
... | [
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid ... |
DB00530 | DB00615 | 1,195 | 690 | [
"DDInter667",
"DDInter1589"
] | Erlotinib | Rifabutin | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Moderate | 1 | [
[
[
1195,
24,
690
]
],
[
[
1195,
24,
463
],
[
463,
1,
690
]
],
[
[
1195,
6,
8374
],
[
8374,
45,
690
]
],
[
[
1195,
7,
3727
],
[
3727,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound)
Erlotinib (Compound) upregulates MAL (Gene) and MAL (Gene) is upregula... |
DB06228 | DB06603 | 792 | 39 | [
"DDInter1609",
"DDInter1387"
] | Rivaroxaban | Panobinostat | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
792,
25,
39
]
],
[
[
792,
63,
336
],
[
336,
24,
39
]
],
[
[
792,
25,
578
],
[
578,
63,
39
]
],
[
[
792,
24,
1478
],
[
1478,
63,
... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedi... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Rivaroxaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may ca... |
DB06626 | DB12500 | 263 | 283 | [
"DDInter147",
"DDInter714"
] | Axitinib | Fedratinib | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
263,
24,
283
]
],
[
[
263,
24,
351
],
[
351,
23,
283
]
],
[
[
263,
63,
122
],
[
122,
23,
283
]
],
[
[
263,
24,
1339
],
[
1339,
6... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may... |
DB00486 | DB08883 | 1,614 | 1,597 | [
"DDInter1253",
"DDInter1428"
] | Nabilone | Perampanel | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
1614,
24,
1597
]
],
[
[
1614,
24,
100
],
[
100,
24,
1597
]
],
[
[
1614,
63,
128
],
[
128,
24,
1597
]
],
[
[
1614,
40,
530
],
[
530,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB05015 | DB12332 | 1,077 | 1,619 | [
"DDInter174",
"DDInter1626"
] | Belinostat | Rucaparib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1077,
24,
1619
]
],
[
[
1077,
24,
259
],
[
259,
24,
1619
]
],
[
[
1077,
24,
151
],
[
151,
63,
1619
]
],
[
[
1077,
63,
1257
],
[
1257,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/Ca... |
DB00099 | DB06650 | 440 | 1,500 | [
"DDInter735",
"DDInter1324"
] | Filgrastim | Ofatumumab | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Moderate | 1 | [
[
[
440,
24,
1500
]
],
[
[
440,
24,
869
],
[
869,
24,
1500
]
],
[
[
440,
24,
1362
],
[
1362,
63,
1500
]
],
[
[
440,
63,
599
],
[
599,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib m... |
DB00624 | DB00704 | 1,561 | 267 | [
"DDInter1775",
"DDInter1263"
] | Testosterone | Naltrexone | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1561,
24,
267
]
],
[
[
1561,
6,
4973
],
[
4973,
45,
267
]
],
[
[
1561,
7,
2900
],
[
2900,
46,
267
]
],
[
[
1561,
18,
6168
],
[
6168,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Testosterone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Testosterone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound)
Testosterone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Naltrexone (Compound)
Testosterone (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is downregulated by Naltrexone (Compound)
Testos... |
DB09038 | DB11921 | 1,450 | 1,019 | [
"DDInter636",
"DDInter492"
] | Empagliflozin | Deflazacort | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1450,
24,
1019
]
],
[
[
1450,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
1450,
24,
192
],
[
192,
24,
1019
]
],
[
[
1450,
63,
443
],
[
443,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Esterified estroge... |
DB00554 | DB00631 | 1,027 | 372 | [
"DDInter1478",
"DDInter405"
] | Piroxicam | Clofarabine | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
1027,
24,
372
]
],
[
[
1027,
6,
7720
],
[
7720,
46,
372
]
],
[
[
1027,
63,
1560
],
[
1560,
24,
372
]
],
[
[
1027,
24,
738
],
[
738,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound... | Piroxicam (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Clofarabine (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Piroxicam ... |
DB00934 | DB09076 | 413 | 1,116 | [
"DDInter1124",
"DDInter1899"
] | Maprotiline | Umeclidinium | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
413,
24,
1116
]
],
[
[
413,
24,
849
],
[
849,
24,
1116
]
],
[
[
413,
63,
1442
],
[
1442,
24,
1116
]
],
[
[
413,
24,
103
],
[
103,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and S... |
DB00242 | DB00773 | 1,064 | 896 | [
"DDInter392",
"DDInter702"
] | Cladribine | Etoposide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Major | 2 | [
[
[
1064,
25,
896
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
896
]
],
[
[
1064,
6,
17404
],
[
17404,
45,
896
]
],
[
[
1064,
7,
7335
],
[
7335... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etoposide"
]
],
[
[
"Cladribine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by... | Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Etoposide (Compound)
Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Etoposide (Compound)
Cladribine (Compound) upregulates LIG1 (Gene) and LIG1 (Gene) is upregulated by Etoposide (Compound)
Cl... |
DB08880 | DB11581 | 1,510 | 1,456 | [
"DDInter1771",
"DDInter1926"
] | Teriflunomide | Venetoclax | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1510,
25,
1456
]
],
[
[
1510,
64,
259
],
[
259,
24,
1456
]
],
[
[
1510,
24,
1129
],
[
1129,
63,
1456
]
],
[
[
1510,
25,
1476
],
[
1476... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
... | Teriflunomide may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 ... |
DB10315 | DB11988 | 1,137 | 270 | [
"DDInter1127",
"DDInter1321"
] | Measles virus vaccine live attenuated | Ocrelizumab | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Major | 2 | [
[
[
1137,
25,
270
]
],
[
[
1137,
64,
134
],
[
134,
24,
270
]
],
[
[
1137,
25,
1019
],
[
1019,
24,
270
]
],
[
[
1137,
25,
398
],
[
398,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vi... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken... |
DB00196 | DB13179 | 600 | 68 | [
"DDInter743",
"DDInter1882"
] | Fluconazole | Troleandomycin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
600,
24,
68
]
],
[
[
600,
23,
1601
],
[
1601,
23,
68
]
],
[
[
600,
24,
1374
],
[
1374,
23,
68
]
],
[
[
600,
24,
309
],
[
309,
24... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Loratadine"
],
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Loratadine and Loratadine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abi... |
DB01191 | DB01233 | 1,039 | 1,311 | [
"DDInter518",
"DDInter1197"
] | Dexfenfluramine | Metoclopramide | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1039,
24,
1311
]
],
[
[
1039,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
1039,
63,
1479
],
[
1479,
23,
1311
]
],
[
[
1039,
25,
643
],
[
64... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Dexfenfluramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v... | Dexfenfluramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken wi... |
DB00011 | DB00193 | 1,451 | 534 | [
"DDInter944",
"DDInter1841"
] | Interferon alfa-n1 | Tramadol | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Major | 2 | [
[
[
1451,
25,
534
]
],
[
[
1451,
24,
112
],
[
112,
62,
534
]
],
[
[
1451,
24,
770
],
[
770,
63,
534
]
],
[
[
1451,
25,
976
],
[
976,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tramadol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Tha... |
DB04865 | DB06203 | 4 | 1,002 | [
"DDInter1335",
"DDInter51"
] | Omacetaxine mepesuccinate | Alogliptin | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
4,
24,
1002
]
],
[
[
4,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
4,
63,
521
],
[
521,
24,
1002
]
],
[
[
4,
24,
1616
],
[
1616,
63,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a m... |
DB09054 | DB14731 | 384 | 1,518 | [
"DDInter905",
"DDInter1741"
] | Idelalisib | Tagraxofusp | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
384,
24,
1518
]
],
[
[
384,
63,
1324
],
[
1324,
24,
1518
]
],
[
[
384,
24,
1613
],
[
1613,
24,
1518
]
],
[
[
384,
23,
1627
],
[
1627,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon be... |
DB01236 | DB01259 | 679 | 392 | [
"DDInter1664",
"DDInter1024"
] | Sevoflurane | Lapatinib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
679,
24,
392
]
],
[
[
679,
6,
8374
],
[
8374,
45,
392
]
],
[
[
679,
21,
28883
],
[
28883,
60,
392
]
],
[
[
679,
62,
112
],
[
112,
... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Sevoflurane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Sevoflurane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Sevoflurane (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Lapatinib (Compound)
Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazol... |
DB00189 | DB01114 | 459 | 272 | [
"DDInter691",
"DDInter362"
] | Ethchlorvynol | Chlorpheniramine | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
459,
24,
272
]
],
[
[
459,
24,
849
],
[
849,
63,
272
]
],
[
[
459,
24,
128
],
[
128,
24,
272
]
],
[
[
459,
25,
475
],
[
475,
24,... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Dexbromph... |
DB11601 | DB12001 | 1,270 | 564 | [
"DDInter1889",
"DDInter7"
] | Tuberculin purified protein derivative | Abemaciclib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1270,
24,
564
]
],
[
[
1270,
63,
58
],
[
58,
24,
564
]
],
[
[
1270,
24,
351
],
[
351,
24,
564
]
],
[
[
1270,
24,
1476
],
[
1476,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Tuberculin purified protein derivative may cause a moderate interaction that could ex... |
DB00176 | DB15091 | 529 | 676 | [
"DDInter770",
"DDInter1901"
] | Fluvoxamine | Upadacitinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
529,
24,
676
]
],
[
[
529,
24,
283
],
[
283,
24,
676
]
],
[
[
529,
24,
891
],
[
891,
25,
676
]
],
[
[
529,
63,
273
],
[
273,
25,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and ... |
DB00635 | DB11095 | 1,573 | 235 | [
"DDInter1515",
"DDInter505"
] | Prednisone | Desirudin | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
1573,
25,
235
]
],
[
[
1573,
24,
1004
],
[
1004,
24,
235
]
],
[
[
1573,
62,
1461
],
[
1461,
24,
235
]
],
[
[
1573,
63,
529
],
[
529,
... | [
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phen... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Prednisone may cause a minor interaction that can limit clinical effects when taken with Vitamin E ... |
DB08873 | DB11986 | 74 | 484 | [
"DDInter221",
"DDInter648"
] | Boceprevir | Entrectinib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
74,
25,
484
]
],
[
[
74,
24,
466
],
[
466,
62,
484
]
],
[
[
74,
25,
1135
],
[
1135,
23,
484
]
],
[
[
74,
63,
510
],
[
510,
24,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolut... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Boceprevir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause... |
DB06589 | DB14783 | 1,250 | 287 | [
"DDInter1400",
"DDInter574"
] | Pazopanib | Diroximel fumarate | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1250,
24,
287
]
],
[
[
1250,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1250,
25,
384
],
[
384,
24,
287
]
],
[
[
1250,
24,
1619
],
[
1619,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Pazopanib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may ... |
DB00431 | DB06204 | 1,503 | 768 | [
"DDInter1072",
"DDInter1746"
] | Lindane | Tapentadol | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
1503,
24,
768
]
],
[
[
1503,
21,
28921
],
[
28921,
60,
768
]
],
[
[
1503,
24,
1383
],
[
1383,
63,
768
]
],
[
[
1503,
24,
104
],
[
104,... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by ... | Lindane (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tapentadol (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Tapen... |
DB01233 | DB09291 | 1,311 | 741 | [
"DDInter1197",
"DDInter1615"
] | Metoclopramide | Rolapitant | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
1311,
24,
741
]
],
[
[
1311,
63,
211
],
[
211,
23,
741
]
],
[
[
1311,
63,
506
],
[
506,
24,
741
]
],
[
[
1311,
25,
924
],
[
924,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorp... |
DB00690 | DB09154 | 1,216 | 1,475 | [
"DDInter762",
"DDInter1686"
] | Flurazepam | Sodium citrate | A benzodiazepine derivative used mainly as a hypnotic. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
1216,
23,
1475
]
],
[
[
1216,
1,
902
],
[
902,
23,
1475
]
],
[
[
1216,
40,
523
],
[
523,
23,
1475
]
],
[
[
1216,
24,
478
],
[
478,
... | [
[
[
"Flurazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a minor int... | Flurazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Flurazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
... |
DB08882 | DB09082 | 1,281 | 659 | [
"DDInter1070",
"DDInter1934"
] | Linagliptin | Vilanterol | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1281,
24,
659
]
],
[
[
1281,
63,
1220
],
[
1220,
23,
659
]
],
[
[
1281,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1281,
63,
323
],
[
323,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglude... |
DB08870 | DB11003 | 850 | 748 | [
"DDInter228",
"DDInter100"
] | Brentuximab vedotin | Anthrax vaccine | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
850,
24,
748
]
],
[
[
850,
63,
322
],
[
322,
24,
748
]
],
[
[
850,
24,
564
],
[
564,
63,
748
]
],
[
[
850,
25,
676
],
[
676,
63,... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epir... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00563 | DB09498 | 663 | 810 | [
"DDInter1174",
"DDInter1715"
] | Methotrexate | Strontium chloride Sr-89 | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
663,
24,
810
]
],
[
[
663,
63,
552
],
[
552,
24,
810
]
],
[
[
663,
24,
1224
],
[
1224,
24,
810
]
],
[
[
663,
24,
1480
],
[
1480,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustin... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Cyt... |
DB01173 | DB04843 | 358 | 1,511 | [
"DDInter1349",
"DDInter1149"
] | Orphenadrine | Mepenzolate | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
358,
24,
1511
]
],
[
[
358,
1,
675
],
[
675,
24,
1511
]
],
[
[
358,
24,
537
],
[
537,
24,
1511
]
],
[
[
358,
63,
1192
],
[
1192,
... | [
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u... | Orphenadrine (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate int... |
DB02546 | DB09054 | 137 | 384 | [
"DDInter1947",
"DDInter905"
] | Vorinostat | Idelalisib | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
137,
24,
384
]
],
[
[
137,
24,
761
],
[
761,
24,
384
]
],
[
[
137,
64,
556
],
[
556,
24,
384
]
],
[
[
137,
63,
473
],
[
473,
24,... | [
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
... | Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Vorinostat may lead to a major life threatening interaction when taken with Valproic acid and Valproic acid ma... |
DB00387 | DB00782 | 1,386 | 1,123 | [
"DDInter1528",
"DDInter1535"
] | Procyclidine | Propantheline | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
1386,
24,
1123
]
],
[
[
1386,
6,
7992
],
[
7992,
45,
1123
]
],
[
[
1386,
24,
537
],
[
537,
63,
1123
]
],
[
[
1386,
35,
1192
],
[
1192,... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Procyclidine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compou... | Procyclidine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Propantheline (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Procyclidine... |
DB01067 | DB01294 | 959 | 266 | [
"DDInter826",
"DDInter215"
] | Glipizide | Bismuth subsalicylate | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
959,
24,
266
]
],
[
[
959,
21,
28929
],
[
28929,
60,
266
]
],
[
[
959,
24,
1254
],
[
1254,
63,
266
]
],
[
[
959,
40,
1411
],
[
1411,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Glipizide",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"... | Glipizide (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Bismuth subsalicylate (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exac... |
DB01165 | DB09043 | 1,539 | 135 | [
"DDInter1325",
"DDInter36"
] | Ofloxacin | Albiglutide | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1539,
24,
135
]
],
[
[
1539,
64,
126
],
[
126,
23,
135
]
],
[
[
1539,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1539,
40,
739
],
[
739,
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Ofloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor int... |
DB00574 | DB09564 | 121 | 1,296 | [
"DDInter717",
"DDInter930"
] | Fenfluramine | Insulin degludec | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
121,
24,
1296
]
],
[
[
121,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
121,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
121,
64,
1230
],
[
1230,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metformin... |
DB01036 | DB09039 | 211 | 1,670 | [
"DDInter1832",
"DDInter629"
] | Tolterodine | Eliglustat | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Minor | 0 | [
[
[
211,
23,
1670
]
],
[
[
211,
62,
121
],
[
121,
24,
1670
]
],
[
[
211,
35,
272
],
[
272,
24,
1670
]
],
[
[
211,
24,
478
],
[
478,
... | [
[
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fenfluramine"
],
[
... | Tolterodine may cause a minor interaction that can limit clinical effects when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Tolterodine (Compound) resembles Chlorpheniramine (Compound) and Tolterodine may cause a moderate interaction... |
DB00697 | DB08881 | 876 | 868 | [
"DDInter1821",
"DDInter1925"
] | Tizanidine | Vemurafenib | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
876,
25,
868
]
],
[
[
876,
6,
7950
],
[
7950,
45,
868
]
],
[
[
876,
18,
8386
],
[
8386,
46,
868
]
],
[
[
876,
18,
4893
],
[
4893,
... | [
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Tizanidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Vemurafenib (Compound)
Tizanidine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Tizanidine (Compound) downregulates S100A13 (Gene) and S100A13 (Gene) is downregulated by Vemurafenib (Compound)
Tiz... |
DB08889 | DB11330 | 350 | 979 | [
"DDInter299",
"DDInter709"
] | Carfilzomib | Factor IX Complex (Human) | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (St... | Major | 2 | [
[
[
350,
25,
979
]
],
[
[
350,
64,
335
],
[
335,
25,
979
]
],
[
[
350,
21,
28762
],
[
28762,
60,
335
],
[
335,
25,
979
]
],
[
[
350,
... | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Factor IX Complex (Human)"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tranexamic acid"
],
[
"Tra... | Carfilzomib may lead to a major life threatening interaction when taken with Tranexamic acid and Tranexamic acid may lead to a major life threatening interaction when taken with Factor IX Complex (Human)
Carfilzomib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tranexamic acid (Compou... |
DB05541 | DB06691 | 801 | 849 | [
"DDInter239",
"DDInter1155"
] | Brivaracetam | Mepyramine | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
801,
24,
849
]
],
[
[
801,
63,
1594
],
[
1594,
24,
849
]
],
[
[
801,
24,
407
],
[
407,
63,
849
]
],
[
[
801,
24,
516
],
[
516,
2... | [
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium m... |
DB00774 | DB00986 | 1,577 | 1,192 | [
"DDInter889",
"DDInter834"
] | Hydroflumethiazide | Glycopyrronium | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Minor | 0 | [
[
[
1577,
23,
1192
]
],
[
[
1577,
23,
1511
],
[
1511,
63,
1192
]
],
[
[
1577,
62,
262
],
[
262,
24,
1192
]
],
[
[
1577,
21,
28835
],
[
288... | [
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mepenzolate... | Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Cli... |
DB00086 | DB10897 | 1,167 | 539 | [
"DDInter1712",
"DDInter291"
] | Streptokinase | Capsicum | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1167,
23,
539
]
],
[
[
1167,
24,
885
],
[
885,
23,
539
]
],
[
[
1167,
25,
1226
],
[
1226,
23,
539
]
],
[
[
1167,
64,
1432
],
[
1432,
... | [
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Streptokinase may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may ca... |
DB08899 | DB11828 | 129 | 1,406 | [
"DDInter649",
"DDInter1281"
] | Enzalutamide | Neratinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
129,
25,
1406
]
],
[
[
129,
25,
1135
],
[
1135,
23,
1406
]
],
[
[
129,
63,
392
],
[
392,
24,
1406
]
],
[
[
129,
24,
710
],
[
710,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} ... | Enzalutamide may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a m... |
DB00741 | DB11057 | 167 | 720 | [
"DDInter885",
"DDInter1223"
] | Hydrocortisone | Mineral oil | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
167,
24,
720
]
],
[
[
167,
1,
175
],
[
175,
24,
720
]
],
[
[
167,
63,
323
],
[
323,
24,
720
]
],
[
[
167,
24,
609
],
[
609,
24,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may ... | Hydrocortisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause ... |
DB00687 | DB00800 | 870 | 572 | [
"DDInter747",
"DDInter720"
] | Fludrocortisone | Fenoldopam | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Moderate | 1 | [
[
[
870,
24,
572
]
],
[
[
870,
21,
28931
],
[
28931,
60,
572
]
],
[
[
870,
1,
1220
],
[
1220,
63,
572
]
],
[
[
870,
1,
1573
],
[
1573,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side E... | Fludrocortisone (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Fenoldopam (Compound)
Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam
Fludrocortisone (Compoun... |
DB08880 | DB09061 | 1,510 | 1,627 | [
"DDInter1771",
"DDInter284"
] | Teriflunomide | Cannabidiol | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Major | 2 | [
[
[
1510,
25,
1627
]
],
[
[
1510,
64,
609
],
[
609,
23,
1627
]
],
[
[
1510,
25,
384
],
[
384,
23,
1627
]
],
[
[
1510,
25,
351
],
[
351,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cannabidiol"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin... | Teriflunomide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a ... |
DB00794 | DB09075 | 759 | 498 | [
"DDInter1521",
"DDInter621"
] | Primidone | Edoxaban | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
759,
24,
498
]
],
[
[
759,
24,
222
],
[
222,
24,
498
]
],
[
[
759,
25,
1017
],
[
1017,
63,
498
]
],
[
[
759,
1,
697
],
[
697,
24... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Primidone may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a ... |
DB00476 | DB06691 | 109 | 849 | [
"DDInter608",
"DDInter1155"
] | Duloxetine | Mepyramine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
109,
24,
849
]
],
[
[
109,
63,
1594
],
[
1594,
24,
849
]
],
[
[
109,
24,
272
],
[
272,
24,
849
]
],
[
[
109,
6,
12523
],
[
12523,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and ... |
DB00983 | DB08903 | 480 | 996 | [
"DDInter776",
"DDInter170"
] | Formoterol | Bedaquiline | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
480,
24,
996
]
],
[
[
480,
21,
29282
],
[
29282,
60,
996
]
],
[
[
480,
24,
144
],
[
144,
63,
996
]
],
[
[
480,
24,
1130
],
[
1130,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Arrhythmia"
],
[
"Arrhythmia",
"{u} (Side Effect) is c... | Formoterol (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bedaquiline (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Beda... |
DB06626 | DB11986 | 263 | 484 | [
"DDInter147",
"DDInter648"
] | Axitinib | Entrectinib | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
263,
24,
484
]
],
[
[
263,
63,
998
],
[
998,
24,
484
]
],
[
[
263,
24,
1320
],
[
1320,
24,
484
]
],
[
[
263,
24,
242
],
[
242,
6... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Ela... |
DB04932 | DB06603 | 1,564 | 39 | [
"DDInter491",
"DDInter1387"
] | Defibrotide | Panobinostat | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1564,
25,
39
]
],
[
[
1564,
25,
578
],
[
578,
63,
39
]
],
[
[
1564,
63,
383
],
[
383,
24,
39
]
],
[
[
1564,
64,
4
],
[
4,
24,
... | [
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{... | Defibrotide may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosa... |
DB01619 | DB11915 | 830 | 1,293 | [
"DDInter1441",
"DDInter1909"
] | Phenindamine | Valbenazine | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
830,
24,
1293
]
],
[
[
830,
24,
516
],
[
516,
24,
1293
]
],
[
[
830,
63,
401
],
[
401,
24,
1293
]
],
[
[
830,
40,
104
],
[
104,
... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Prometha... |
DB00902 | DB01579 | 104 | 341 | [
"DDInter1168",
"DDInter1439"
] | Methdilazine | Phendimetrazine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
104,
24,
341
]
],
[
[
104,
24,
959
],
[
959,
24,
341
]
],
[
[
104,
24,
1281
],
[
1281,
63,
341
]
],
[
[
104,
63,
127
],
[
127,
2... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin an... |
DB11642 | DB11901 | 938 | 913 | [
"DDInter1480",
"DDInter107"
] | Pitolisant | Apalutamide | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
938,
25,
913
]
],
[
[
938,
62,
112
],
[
112,
23,
913
]
],
[
[
938,
63,
600
],
[
600,
24,
913
]
],
[
[
938,
25,
877
],
[
877,
63,... | [
[
[
"Pitolisant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Pitolisant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB00108 | DB11003 | 1,066 | 748 | [
"DDInter1268",
"DDInter100"
] | Natalizumab | Anthrax vaccine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1066,
24,
748
]
],
[
[
1066,
25,
322
],
[
322,
24,
748
]
],
[
[
1066,
25,
564
],
[
564,
63,
748
]
],
[
[
1066,
64,
816
],
[
816,
... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epi... | Natalizumab may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Natalizumab may lead to a major life threatening interaction when taken with Abemaciclib and Abemaciclib may cause a mode... |
DB00015 | DB06209 | 582 | 256 | [
"DDInter1585",
"DDInter1508"
] | Reteplase | Prasugrel | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
582,
25,
256
]
],
[
[
582,
23,
944
],
[
944,
62,
256
]
],
[
[
582,
24,
901
],
[
901,
24,
256
]
],
[
[
582,
24,
1427
],
[
1427,
6... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran ma... |
DB00332 | DB09488 | 1,089 | 103 | [
"DDInter970",
"DDInter23"
] | Ipratropium | Acrivastine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1089,
24,
103
]
],
[
[
1089,
24,
1405
],
[
1405,
24,
103
]
],
[
[
1089,
63,
357
],
[
357,
24,
103
]
],
[
[
1089,
24,
1536
],
[
1536,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Benzatro... |
DB00327 | DB00434 | 421 | 13 | [
"DDInter890",
"DDInter459"
] | Hydromorphone | Cyproheptadine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
421,
24,
13
]
],
[
[
421,
24,
104
],
[
104,
63,
13
]
],
[
[
421,
21,
28789
],
[
28789,
60,
13
]
],
[
[
421,
63,
352
],
[
352,
24... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
... | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Hydromorphone (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side E... |
DB01166 | DB06288 | 477 | 607 | [
"DDInter379",
"DDInter77"
] | Cilostazol | Amisulpride | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
477,
25,
607
]
],
[
[
477,
21,
29232
],
[
29232,
60,
607
]
],
[
[
477,
62,
112
],
[
112,
23,
607
]
],
[
[
477,
63,
1559
],
[
1559,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Cilostazol",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Com... | Cilostazol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amis... |
DB00153 | DB00312 | 1,331 | 1,023 | [
"DDInter662",
"DDInter1423"
] | Ergocalciferol | Pentobarbital | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Moderate | 1 | [
[
[
1331,
24,
1023
]
],
[
[
1331,
24,
288
],
[
288,
40,
1023
]
],
[
[
1331,
6,
8374
],
[
8374,
45,
1023
]
],
[
[
1331,
21,
28722
],
[
2872... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound)
Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pentobarbital (Compound)
Ergocalciferol (Compound) causes Nausea (Side Effect... |
DB00215 | DB01142 | 1,230 | 1,264 | [
"DDInter388",
"DDInter593"
] | Citalopram | Doxepin | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1230,
25,
1264
]
],
[
[
1230,
25,
401
],
[
401,
24,
1264
]
],
[
[
1230,
24,
832
],
[
832,
24,
1264
]
],
[
[
1230,
24,
649
],
[
649,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} ... | Citalopram may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine m... |
DB00647 | DB01575 | 675 | 1,054 | [
"DDInter528",
"DDInter1005"
] | Dextropropoxyphene | Kaolin | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
675,
24,
1054
]
],
[
[
675,
25,
407
],
[
407,
63,
1054
]
],
[
[
675,
40,
576
],
[
576,
24,
1054
]
],
[
[
675,
1,
1301
],
[
1301,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opi... | Dextropropoxyphene may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Dextropropoxyphene (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate dis... |
DB00377 | DB00726 | 1,494 | 1,164 | [
"DDInter1382",
"DDInter1876"
] | Palonosetron | Trimipramine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Major | 2 | [
[
[
1494,
25,
1164
]
],
[
[
1494,
25,
1237
],
[
1237,
40,
1164
]
],
[
[
1494,
24,
508
],
[
508,
40,
1164
]
],
[
[
1494,
64,
576
],
[
576,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimipramine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
... | Palonosetron may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Trimipramine (Compound)
Palon... |
DB00561 | DB06706 | 1,048 | 468 | [
"DDInter591",
"DDInter985"
] | Doxapram | Isometheptene | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
1048,
24,
468
]
],
[
[
1048,
24,
480
],
[
480,
24,
468
]
],
[
[
1048,
24,
144
],
[
144,
63,
468
]
],
[
[
1048,
63,
1290
],
[
1290,
... | [
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodate... |
DB00226 | DB01069 | 1,000 | 401 | [
"DDInter845",
"DDInter1533"
] | Guanadrel | Promethazine | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1000,
24,
401
]
],
[
[
1000,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1000,
24,
1614
],
[
1614,
24,
401
]
],
[
[
1000,
63,
245
],
[
245,
... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may c... |
DB06317 | DB08871 | 1,626 | 36 | [
"DDInter630",
"DDInter666"
] | Elotuzumab | Eribulin | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1626,
24,
36
]
],
[
[
1626,
24,
221
],
[
221,
63,
36
]
],
[
[
1626,
63,
563
],
[
563,
24,
36
]
],
[
[
1626,
24,
655
],
[
655,
24... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (fo... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Elotuzumab may cause a moderat... |
DB01021 | DB01105 | 674 | 222 | [
"DDInter1861",
"DDInter1665"
] | Trichlormethiazide | Sibutramine | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
674,
24,
222
]
],
[
[
674,
18,
9385
],
[
9385,
57,
222
]
],
[
[
674,
24,
659
],
[
659,
63,
222
]
],
[
[
674,
1,
1014
],
[
1014,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"MRPL19"
],
[
"MRPL19",
"{u} (Gene) is ... | Trichlormethiazide (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound)
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00758 | DB01611 | 1,347 | 1,487 | [
"DDInter413",
"DDInter893"
] | Clopidogrel | Hydroxychloroquine | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1347,
24,
1487
]
],
[
[
1347,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1347,
63,
168
],
[
168,
24,
1487
]
],
[
[
1347,
62,
245
],
[
245... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Clopidogrel",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect)... | Clopidogrel (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00480 | DB11979 | 1,668 | 1,320 | [
"DDInter1035",
"DDInter625"
] | Lenalidomide | Elagolix | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1668,
24,
1320
]
],
[
[
1668,
63,
79
],
[
79,
24,
1320
]
],
[
[
1668,
24,
129
],
[
129,
24,
1320
]
],
[
[
1668,
25,
888
],
[
888,
... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enza... |
DB00344 | DB00927 | 1,302 | 1,559 | [
"DDInter1543",
"DDInter712"
] | Protriptyline | Famotidine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1302,
24,
1559
]
],
[
[
1302,
18,
7359
],
[
7359,
57,
1559
]
],
[
[
1302,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
1302,
1,
109
],
[
10... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Protriptyline",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulat... | Protriptyline (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Famotidine (Compound)
Protriptyline (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Protriptyline (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a minor ... |
DB00559 | DB01181 | 152 | 1,532 | [
"DDInter223",
"DDInter906"
] | Bosentan | Ifosfamide | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
152,
24,
1532
]
],
[
[
152,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
152,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
152,
24,
351
],
[
351,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Bosentan (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribo... |
DB00104 | DB04855 | 966 | 540 | [
"DDInter1323",
"DDInter602"
] | Octreotide | Dronedarone | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
966,
24,
540
]
],
[
[
966,
24,
228
],
[
228,
40,
540
]
],
[
[
966,
21,
28883
],
[
28883,
60,
540
]
],
[
[
966,
23,
466
],
[
466,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dofetilide"
],
[
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Dofetilide and Dofetilide (Compound) resembles Dronedarone (Compound)
Octreotide (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Octreotide may cause a minor inter... |
DB06288 | DB09104 | 607 | 286 | [
"DDInter77",
"DDInter1118"
] | Amisulpride | Magnesium hydroxide | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
607,
24,
286
]
],
[
[
607,
64,
820
],
[
820,
23,
286
]
],
[
[
607,
63,
1559
],
[
1559,
23,
286
]
],
[
[
607,
63,
688
],
[
688,
2... | [
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
... | Amisulpride may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Amisulpride may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine... |
DB00682 | DB01299 | 126 | 698 | [
"DDInter1951",
"DDInter1722"
] | Warfarin | Sulfadoxine | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Major | 2 | [
[
[
126,
25,
698
]
],
[
[
126,
25,
1247
],
[
1247,
40,
698
]
],
[
[
126,
64,
1029
],
[
1029,
40,
698
]
],
[
[
126,
64,
161
],
[
161,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
... | Warfarin may lead to a major life threatening interaction when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Warfarin may lead to a major life threatening interaction when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfadoxine (Compound)
Warfarin may l... |
DB00258 | DB01021 | 666 | 674 | [
"DDInter270",
"DDInter1861"
] | Calcium acetate | Trichlormethiazide | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
666,
24,
674
]
],
[
[
666,
24,
1014
],
[
1014,
40,
674
]
],
[
[
666,
24,
178
],
[
178,
1,
674
]
],
[
[
666,
63,
964
],
[
964,
23... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiaz... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resemb... |
DB01083 | DB01125 | 1,142 | 279 | [
"DDInter1348",
"DDInter98"
] | Orlistat | Anisindione | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
1142,
24,
279
]
],
[
[
1142,
63,
1647
],
[
1647,
23,
279
]
],
[
[
1142,
63,
912
],
[
912,
24,
279
]
],
[
[
1142,
24,
123
],
[
123,
... | [
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"... | Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interfe... |
DB00313 | DB00945 | 556 | 1,479 | [
"DDInter1913",
"DDInter20"
] | Valproic acid | Acetylsalicylic acid | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
556,
24,
1479
]
],
[
[
556,
24,
316
],
[
316,
40,
1479
]
],
[
[
556,
6,
10215
],
[
10215,
45,
1479
]
],
[
[
556,
5,
11610
],
[
11610,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanid... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide and Nitazoxanide (Compound) resembles Acetylsalicylic acid (Compound)
Valproic acid (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Acetylsalicylic acid (Compound)
Valproic acid (Compound) treats mi... |
DB00054 | DB01242 | 1,432 | 1,237 | [
"DDInter6",
"DDInter410"
] | Abciximab | Clomipramine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1432,
24,
1237
]
],
[
[
1432,
64,
1578
],
[
1578,
24,
1237
]
],
[
[
1432,
24,
1274
],
[
1274,
24,
1237
]
],
[
[
1432,
25,
498
],
[
498... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",... | Abciximab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may caus... |
DB00722 | DB09146 | 743 | 489 | [
"DDInter1079",
"DDInter978"
] | Lisinopril | Iron sucrose | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Moderate | 1 | [
[
[
743,
24,
489
]
],
[
[
743,
1,
1058
],
[
1058,
24,
489
]
],
[
[
743,
40,
1638
],
[
1638,
24,
489
]
],
[
[
743,
1,
1058
],
[
1058,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a moderat... | Lisinopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iron su... |
DB00390 | DB06285 | 1,252 | 65 | [
"DDInter554",
"DDInter1772"
] | Digoxin | Teriparatide | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of... | Moderate | 1 | [
[
[
1252,
24,
65
]
],
[
[
1252,
1,
1482
],
[
1482,
24,
65
]
],
[
[
1252,
18,
19625
],
[
19625,
46,
504
],
[
504,
23,
65
]
],
[
[
1252,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriparatide"
]
],
[
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a moderate inte... | Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Teriparatide
Digoxin (Compound) downregulates CCDC92 (Gene) and CCDC92 (Gene) is upregulated by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interac... |
DB08871 | DB11627 | 36 | 1,367 | [
"DDInter666",
"DDInter860"
] | Eribulin | Hepatitis B Vaccine (Recombinant) | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
36,
24,
1367
]
],
[
[
36,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
36,
24,
1480
],
[
1480,
24,
1367
]
],
[
[
36,
63,
259
],
[
259,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
... | Eribulin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixaz... |
DB00065 | DB01157 | 581 | 304 | [
"DDInter923",
"DDInter1875"
] | Infliximab | Trimetrexate | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Major | 2 | [
[
[
581,
25,
304
]
],
[
[
581,
24,
58
],
[
58,
24,
304
]
],
[
[
581,
24,
1270
],
[
1270,
63,
304
]
],
[
[
581,
25,
139
],
[
139,
24,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimetrexate"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified p... |
DB01089 | DB09241 | 1,340 | 1,629 | [
"DDInter502",
"DDInter1186"
] | Deserpidine | Methylene blue | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Moderate | 1 | [
[
[
1340,
24,
1629
]
],
[
[
1340,
63,
1148
],
[
1148,
24,
1629
]
],
[
[
1340,
1,
1245
],
[
1245,
24,
1629
]
],
[
[
1340,
63,
73
],
[
73,
... | [
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Deserpidine (Compound) resembles Reserpine (Compound) and Reserpine may cause a moderate interaction th... |
DB01208 | DB09330 | 945 | 985 | [
"DDInter1705",
"DDInter1352"
] | Sparfloxacin | Osimertinib | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
945,
25,
985
]
],
[
[
945,
62,
112
],
[
112,
23,
985
]
],
[
[
945,
62,
134
],
[
134,
24,
985
]
],
[
[
945,
63,
480
],
[
480,
24,... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.